Drug & intervention

Saxenda

RxCUI 1598264

Clinical trials6

Recruiting0

Related conditions8

Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

6 shown

The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot StudyNCT06217848 · 2022-11-28

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With ObesityNCT05111912 · 2021-11-30

3mg Liraglutide for Overweight or ObesityNCT03885297 · 2019-01-18

Saxenda in Obesity Services (STRIVE Study)NCT03036800 · 2017-11-28

Effect of GLP-1 Receptor Agonism After Sleeve GastrectomyNCT03115424 · 2017-06-22

Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass SurgeryNCT03048578 · 2017-05-22

Conditions being studied

Obesity5 Craniopharyngioma1 Diabetes Mellitus1 Hypothalamic Obesity1 Infertility, Female1 Overweight1 Panhypopituitarism1 Weight Loss1

Research locations

DublinIreland1 GlasgowUnited Kingdom1 LeicesterUnited Kingdom1 LiverpoolUnited Kingdom1 LondonUnited Kingdom1 New YorkNew York, United States1 RochesterMinnesota, United States1

Leading sponsors

Mayo Clinic1 NYU Langone Health1 Sciwind Biosciences APAC CO Pty. Ltd.1 Seoul National University Hospital1 University Hospitals Coventry and Warwickshire NHS Trust1 University of Leicester1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.